Drug profile · INN
glycopyrrolate
GLYCOPYRROLATE
glycopyrrolate (GLYCOPYRROLATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
Drug details — glycopyrrolate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 0
- Data quality
- 0.89
Quick answer
glycopyrrolate (GLYCOPYRROLATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is glycopyrrolate?
glycopyrrolate (GLYCOPYRROLATE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glycopyrrolate?
GLYCOPYRROLATE is a marketed brand name for glycopyrrolate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glycopyrrolate?
glycopyrrolate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.